methylprednisolone + prednisone (Beijing Tiantan Hospital)

This drug entry refers to a specific sequential steroid regimen evaluated by **Beijing Tiantan Hospital** in the Phase 3 SAF-NRVS clinical trial. The protocol consists of an initial course of intravenous **methylprednisolone sodium succinate** (80 mg once daily) from the day of surgery through day 3, followed by oral **prednisone acetate** (20 mg once daily) from day 4 to day 10. This regimen is designed to preserve facial nerve function in adult patients undergoing craniotomy for the removal of unilateral vestibular schwannoma (acoustic neuroma). Both components are synthetic glucocorticoids that function as glucocorticoid receptor agonists, exerting potent anti-inflammatory effects to mitigate post-surgical edema and inflammatory damage to the facial nerve, which is often at risk during skull base surgery.

Other names

Steroids therapyPerioperative steroidsMethylprednisolone sodium succinate + prednisone acetate